Materialise Nv Stock Earnings Reports

Key points for investors:

- Strategic portfolio simplification: Materialise transferred its RapidFit and eyewear businesses to their respective management teams (Materialise retains a minority stake in eyewear). These moves are meant to sharpen focus and reallocate capital and leadership to core segments. Financial terms were not disclosed.

- Medical segment momentum: Medical revenue grew 7% YoY to €33.2m (would be double-digit on a constant currency basis). Notable product launches include custom-made PEEK cranio‑maxillofacial implants (now available across most of Europe) and OrthoView 3D Hip (CT‑based planning), both positioned to leverage Materialise’s integrated digital ecosystem. Medical adjusted EBITDA margin was 20%.

- Software progress and partnerships: Software revenue declined 1% reported (up ~5% constant currency) with recurring revenue at 83%. CO‑AM (cloud production management) is being rolled out (7 customers onboarding in May; full availability mid‑June) and CO‑AM Brix aims to simplify automation. Materialise announced Magics Print inclusion with HP’s MJF 1200 printer (full solution available early 2027), expanding access to lower/mid-range market segments. Deferred revenue (software maintenance/licenses) increased to €49m within total deferred revenue of €61m.

- Manufacturing trends: Manufacturing revenue declined 8% to €23.5m due to soft prototyping demand and broader macro weakness (notably automotive in Europe), but sequential recovery and growth in aerospace, defense and semiconductor work. The segment returned to positive adjusted EBITDA in Q1 and management expects Manufacturing EBITDA to be positive for full year 2026.

- Strong profitability and balance sheet: Q1 revenue was stable at €66.3m despite FX headwinds. Gross profit rose to €37.9m (gross margin 57.2%). Adjusted EBITDA was €8.0m (12.1% margin), adjusted EBIT €2.5m, and net profit €1.8m (€0.03/share). Net cash position improved to €72.8m with cash reserves of €133m and gross debt of €60.1m; free cash flow was positive (€5.7m after investing).

- Guidance and outlook: Management reaffirmed full‑year 2026 revenue guidance of €273–283m and adjusted EBIT guidance of €10–12m despite the divestments. They expect persistent macro and geopolitical uncertainty but see continued strength in key end markets (aerospace, defense, healthcare) and are emphasizing execution discipline and targeted investments.

- ESG: Published first annual report post‑listing and completed CSRD reporting; exceeded GHG reduction targets (>1,500 tons CO2 reduction over a rolling two‑year period), with material initiatives like carbon‑reduced PA12 and a solar park covering >40% HQ electricity needs.